Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat

被引:87
作者
Barthelemy, S
Vergnes, L
Moynier, M
Guyot, D
Labidalle, S
Bahraoui, E
机构
[1] Univ Toulouse 3, Lab Immunovirol Lentivirus, F-31062 Toulouse, France
[2] Fac Pharm, Lab Synth Physicochim & Radiobiol, F-31062 Toulouse, France
来源
RESEARCH IN VIROLOGY | 1998年 / 149卷 / 01期
关键词
HIV1; Tat protein; transactivation; curcumin; derivatives; inhibition; superoxide;
D O I
10.1016/S0923-2516(97)86899-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The transcription of HIV1 provirus is regulated by both cellular and viral factors. Various evidence suggests that Tat protein secreted by HIV1-infected cells may have additional action in the pathogenesis of AIDS because of its ability to also be taken up by non-infected cells. Curcumin [diferuloylmethane or 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is the yellow pigment in turmeric Curcuma longa (Linn). it exhibits a variety of pharmacological effects including antiinflammatory and antiretroviral activities. Here, we demonstrated that curcumin used at 10 to 100 nM inhibited Tat transactivation of HIV1-LTR lacZ by 70 to 80% in HeLa cells. In order to develop more efficient curcumin derivatives, we synthesized and tested in the same experimental system the inhibitory activity of reduced curcumin (C-1), which lacks the spatial structure of curcumin; allyl-curcumin (C-2), which possesses a condensed allyl derivative on curcumin that plays the role of metal chelator; and tocopheryl-curcumin (C-3), which enhances the antioxidant activity of the molecule. Results obtained with C-1, C-2 and C-3 curcumin derivatives showed a significant inhibition (70 to 85%) of Tat transactivation. Despite the fact that tocopheryl-curcumin (C-3) failed to scavenge O-2(.-), this curcumin derivative exhibited the most activity; 70% inhibition was obtained at 1 nM, while only 35% inhibition was obtained with the curcumin.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 36 条
[11]   SUPEROXIDE-DISMUTASE ASSAY USING ALKALINE DIMETHYLSULFOXIDE AS SUPEROXIDE ANION-GENERATING SYSTEM [J].
HYLAND, K ;
VOISIN, E ;
BANOUN, H ;
AUCLAIR, C .
ANALYTICAL BIOCHEMISTRY, 1983, 135 (02) :280-287
[12]   2-(AMINOMETHYL)CHROMANS THAT INHIBIT IRON-DEPENDENT LIPID-PEROXIDATION AND PROTECT AGAINST CENTRAL-NERVOUS-SYSTEM TRAUMA AND ISCHEMIA [J].
JACOBSEN, EJ ;
VANDOORNIK, FJ ;
AYER, DE ;
BELONGA, KL ;
BRAUGHLER, JM ;
HALL, ED ;
HOUSER, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (23) :4464-4472
[13]   Inhibition of HIV-1 tat-mediated transactivation by quinacrine and chloroquine [J].
Jiang, MC ;
Lin, JK ;
Chen, SSL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 226 (01) :1-7
[14]   Tat and the HIV-1 promoter [J].
Jones, Katherine A. .
CURRENT OPINION IN CELL BIOLOGY, 1993, 5 (03) :461-468
[15]   OXYGEN RADICAL SCAVENGING ACTIVITY OF CURCUMIN [J].
KUNCHANDY, E ;
RAO, MNA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 58 (03) :237-240
[16]   Sensitization of the HIV-1-LTR upon long term low dose oxidative stress [J].
Kurata, SI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (36) :21798-21802
[17]   3 INHIBITORS OF TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS LONG TERMINAL REPEAT-DIRECTED GENE-EXPRESSION AND VIRUS-REPLICATION [J].
LI, CJ ;
ZHANG, LJ ;
DEZUBE, BJ ;
CRUMPACKER, CS ;
PARDEE, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1839-1842
[18]   SPECIFIC NF-KAPPA-B SUBUNITS ACT IN CONCERT WITH TAT TO STIMULATE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSCRIPTION [J].
LIU, JS ;
PERKINS, ND ;
SCHMID, RM ;
NABEL, GJ .
JOURNAL OF VIROLOGY, 1992, 66 (06) :3883-3887
[19]  
LOUPY A, 1987, B SOC CHIM FR, P1027
[20]   CULTURED AIDS-RELATED KAPOSIS-SARCOMA (AIDS-KS) CELLS DEMONSTRATE IMPAIRED BIOENERGETIC ADAPTATION TO OXIDANT CHALLENGE - IMPLICATION FOR OXIDANT STRESS IN AIDS-KS PATHOGENESIS [J].
MALLERY, SR ;
BAILER, RT ;
HOHL, CM ;
NGBAUTISTA, CL ;
NESS, GM ;
LIVINGSTON, BE ;
HOUT, BL ;
STEPHENS, RE ;
BRIERLEY, GP .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, 59 (03) :317-328